Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

CompletedOBSERVATIONAL

Enrollment

296

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

June 11, 2025

Study Completion Date

June 11, 2025

Conditions

Alopecia Totalis/UniversalisAlopecia Areata(AA)

Interventions

DRUG

Tofacitinib

Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.

Trial Locations (1)

Orchid Pharmed, Tehran

All Listed Sponsors

lead

NanoAlvand

INDUSTRY

NCT07101471 - Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation | Biotech Hunter | Biotech Hunter